EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy

Francis Proulx-Rocray, Bertrand Routy, Rami Nassabein, Wiam Belkaid, Danh Tran-Thanh, Julie Malo, Marion Tonneau, Omar El Ouarzadi, Marie Florescu, Mustapha Tehfe, Normand Blais

Cancer Treatment and Research Communications · 2023 · 37 · 100767

DOI: 10.1016/j.ctarc.2023.100767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2023. Verfasst von Francis Proulx-Rocray und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Centre Hospitalier de l'Université de Montréal (CHUM), 1051 Sanguinet Street, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Montreal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: PD-L1 expression is used to predict NSCLC response to ICIs, but its performance is suboptimal. The impact of KRAS mutations in these patients is unclear. Studies evaluating co-mutations in TP53, STK11 and KEAP1 as well as the NLR showed that they may predict the benefit of ICIs. PATIENTS & METHODS: This is a retrospective study of patients with NSCLC treated with ICIs at the CHUM between July 2015 and June 2020. OS and PFS were compared using Kaplan-Meier and logrank methods. Co-mutations in TP53, STK11 and KEAP1 as well as the NLR were accounted for. ORR and safety were compared using Wald method. RESULTS: From 100 patients with known KRAS status, 50 were mutated (KRASMut). Mutation in TP53, STK11 and KEAP1 were present, and their status known in, respectively, 19/40 (47.5 %), 8/39 (20.5 %) and 4/38 (10.5 %) patients. STK11Mut and KEAP1Mut were associated with shorter overall survival when compared with wild type tumors (respectively median OS of 3.3 vs 20.4, p = 0.0001 and 10.1 vs 17.7, p = 0.24). When KRAS status was compounded with STK11/KEAP1, KRASMut trended to a better prognosis in STK11+KEAP1WT tumors (median OS 21.1 vs 15.8 for KRASWT, p = 0.15), but not for STK11+/-KEAP1Mut tumors. The NLR was strongly impacted by STK11 (6.0Mutvs 3.6WT, p = 0.014) and TP53 (3.2Mutvs 4.8WT, p = 0.048), but not by KEAP1 or KRAS mutations. CONCLUSION: STK11Mut and KEAP1Mut are adverse predictors of ICI therapy benefit. The NLR is strongly impacted by STK11Mut but not by KEAP1Mut, suggesting differences in their resistance mechanism. In STK11-KEAP1WT tumors, KRASMut seem associated with improved survival in NSCLC patients treated with ICIs. MICROABSTRACT: Response of NSCLC to immunotherapy is not easily predictable. We conducted a retrospective study in 100 patients with NSCLC and a known KRAS status. By accounting for different co-mutations, KRAS mutation was found to be associated with a better median overall survival in STK11 and KEAP1 wild-type tumors (21.1 vs 15.8, p = 0.15). NLR was impacted by STK11, but not KEAP1 mutation, suggesting a difference in their resistance mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Protein Serine-Threonine KinasesImmunotherapyMutationTumor Suppressor Protein p53AMP-Activated Protein Kinase Kinases

Stichwörter der Autor:innen

ImmunotherapyKEAP1KRASNSCLCSTK11

Substanzen

Proto-Oncogene Proteins p21(ras)Kelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Protein Serine-Threonine KinasesTumor Suppressor Protein p53TP53 protein, humanKRAS protein, humanKEAP1 protein, humanSTK11 protein, humanAMP-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Medical Oncology Department, Centre Hospitalier de l'Université de Montréal (CHUM), 1051 Sanguinet Street, Montreal, QC, Canada.
  • Medical Oncology Department, Centre Hospitalier de l'Université de Montréal (CHUM), 1051 Sanguinet Street, Montreal, QC, Canada; Department of Medicine, Centre de Recherche du Centre Hospitalier de l'Université de Montr…
  • Department of Medicine, Centre de Recherche du Centre Hospitalier de l'Université de Montréal and Institut du Cancer de Montréal, 900 Saint-Denis Street, Montreal, QC, Canada.
  • Pathology Department, Centre Hospitalier de l'Université de Montréal, 1051 Sanguinet Street, Montreal, QC, Canada.

Förderung

  • University of Montreal

Zitieren

APA

Proulx-Rocray, F., Routy, B., Nassabein, R., Belkaid, W., Tran-Thanh, D., Malo, J., Tonneau, M., Ouarzadi, O. E., Florescu, M., Tehfe, M., & Blais, N. (2023). The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Cancer Treatment and Research Communications, 37, 100767. https://doi.org/10.1016/j.ctarc.2023.100767

Vancouver

Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, et al. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Cancer Treatment and Research Communications. 2023;37:100767. doi:10.1016/j.ctarc.2023.100767

BibTeX
@article{ProulxRocray2023,
  author = {Proulx-Rocray, Francis and Routy, Bertrand and Nassabein, Rami and Belkaid, Wiam and Tran-Thanh, Danh and Malo, Julie and Tonneau, Marion and Ouarzadi, Omar El and Florescu, Marie and Tehfe, Mustapha and Blais, Normand},
  title = {The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy},
  journal = {Cancer Treatment and Research Communications},
  year = {2023},
  volume = {37},
  pages = {100767},
  doi = {10.1016/j.ctarc.2023.100767}
}
Kostenlos starten →